Journal of Clinical Oncology
Articles in this Issue
Wait or treat? managing asymptomatic brain metastases in oncogene-mutated NSCLC: Results of a phase-III randomized controlled trial.
8624 Background: The timing of brain radiation therapy (RT) in patients with oncogene-mutated NSCLC with asymptomatic brai...
Omission of postoperative antibiotic prophylaxis after radical cystectomy: Interim results of the A-PURC phase III randomized non-inferiority trial.
e23314 Background: Urinary tract infection (UTI) is a common cause of readmission following radical cystectomy(RC). The op...
Clinicopathological features and prognosis of anaplastic and poorly differentiated thyroid carcinoma: Insights on treatment strategies from a 28-year real-world study spanning the immunotherapy era.
e18145 Background: Anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC) are rare and aggr...
Discrepancy between plasma cell-free DNA and tissue-based analysis for detection of gene amplifications in non–small cell lung cancer.
8537 Background: Therapeutic strategies have been developed in patients with non-small cell lung cancer (NSCLC) harboring...
Baseline gut microbiome and metabolomic profiles associated with durable response to first-line third-generation EGFR-TKIs in patients with advanced EGFR-mutant NSCLC.
e20756 Background: First-line third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) are standard therapy for EGFR-m...
Multi-model prognostic evaluation of immunotherapy in advanced biliary tract cancer and development of the bedside biccaps score: A multicenter study.
e16183 Background: Immune checkpoint inhibitors (ICIs) have improved outcomes for advanced biliary tract cancer (BTC), but...
Tumor-informed ctDNA as a biomarker of outcomes following stereotactic body radiotherapy in metastatic urothelial carcinoma.
e16590 Background: Stereotactic body radiotherapy (SBRT) is used in metastatic urothelial carcinoma (mUC) to defer or augm...
Characterization of toxicities associated with sulfamethoxazole/trimethoprim (TMP-SMX) for pneumocystis jirovecii prophylaxis in patients with glioblastoma (GBM).
e14066 Background: Standard of care treatment for GBM includes temozolomide (TMZ) chemotherapy, which induces significant...
Timing of TP53 mutation acquisition as a determinant of outcomes in patients with myeloproliferative neoplasms and myeloproliferative neoplasms/myelodysplastic syndromes.
6587 Background: While TP53 mutations have been studied in MDS and AML, their clin...
Incidence and genomic characteristics of a low homologous recombination deficiency score subgroup in <i>BRCA</i> -mutant ovarian cancer.
5584 Background: Homologous recombination deficiency (HRD) is a pivotal molecular phenotype in ovarian cancer (OC) and ser...
Correlation of Ki-67 with tumor fraction in metastatic HR-positive invasive lobular and no special type breast cancer.
e13014 Background: Invasive lobular carcinoma (ILC) is characterized by loss of E-cadherin, resulting in an infiltrative,...
Afatinib versus osimertinib for non–small cell lung cancer with uncommon epidermal growth factor receptor mutations: Real-world outcomes (HOT-Next001/HOT2501).
8605 Background: Non–small cell lung cancers (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations exhib...
Real-world impact of human papillomavirus vaccination on cervical cancer incidence and prevalence: A large electronic health record analysis.
e17521 Background: Human papillomavirus (HPV) vaccination is a key preventive strategy against cervical cancer; however, r...
Neighborhood deprivation and nativity in breast cancer stage at diagnosis among U.S.- and Latin America–born women.
e13512 Background: Stage at diagnosis strongly predicts breast cancer outcomes. Socioeconomic and structural factors affec...
Sensitivity of CA-125 by ovarian cancer histology.
e17557 Background: Women with ovarian cancer may have subtle symptoms, delaying diagnosis to late stage. Guidelines recomm...
Impact of immunotherapy era on survival in stage IV non–small cell lung cancer.
8562 Background: The introduction of immunotherapy (IO) has transformed treatment paradigms in Stage IV non-small cell lun...
A SEER-based Joinpoint analysis investigating the effect of shared decision-making on prostate cancer stage at diagnosis.
10521 Background: Prostate cancer screening recommendations in the United States have evolved over the last two decades. T...
Evaluating the impact of a statewide intervention on multiple myeloma bispecific T-cell engaging antibody (BsAb) therapy uptake in Florida (FL).
7532 Background: BsAbs are highly effective, off-the-shelf T-cell engagers recently approved for relapsed/refractory multi...
Shifting drivers of hospitalization in endometrial cancer: Toxicity-like organ failure phenotypes in the modern treatment era.
11066 Background: Frontline endometrial cancer care has rapidly shifted toward immune-based regimens. Whether inpatient ad...
Tumor treating fields therapy in patients with newly diagnosed glioblastoma and poor performance status: Real-world analysis of patients treated in the US.
2044 Background: TTFields therapy is an FDA-approved treatment for patients with newly diagnosed glioblastoma, showing ben...
LUCID: Turning clinical noise into signal, structuring oncology data at scale.
e15507 Background: Most clinically meaningful oncology information is recorded in unstructured formats, limiting its consi...
Updated results of a single-arm phase II clinical trial of gemcitabine, cisplatin, and nab-paclitaxel as neoadjuvant therapy for pancreatic ductal adenocarcinoma.
e16468 Background: Neoadjuvant chemo approach is favored in resectable/borderline resectable (R/BR) pancreatic ductal aden...
Age-vulnerability interaction and real-world treatment outcomes in <i>EGFR</i> -mutant non–small cell lung cancer.
e20685 Background: Older adults with EGFR-mutant metastatic non-small cell lung cancer (NSCLC) are underrepresented in cli...
NALIRIFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer: A phase I study.
3564 Background: FOLFOXIRI combined with targeted therapy is recommended for metastatic colorectal cancer (mCRC) patients...
CDH17 expression and tumor microenvironment composition in gastric cancer.
4033 Background: Cadherin 17 (CDH17), commonly referred to as liver-intestine cadherin, is a calcium-dependent cell adhesi...